Login / Signup

Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).

Yuichiro YamadaMasayuki SendaYusuke NaitoMasahiro TamuraDaisuke WatanabeYujin ShutoYoshihisa Urita
Published in: Diabetes, obesity & metabolism (2017)
Lixisenatide reduced PPG significantly more than sitagliptin, when these agents were added to basal insulin glargine U100, and was well tolerated.
Keyphrases
  • type diabetes
  • glycemic control
  • blood glucose
  • metabolic syndrome
  • blood pressure
  • insulin resistance